TAC1, transcriptional activator of CDR genes, is a new transcription factor involved in the regulation of Candida albicans ABC transporters CDR1 and CDR2

DOI: 10.1128/ec.3.6.1639-1652.2004
Eukaryotic Cell, 2004, 3, 1639-52.

#	Paper	IF	Citations
348	Regulation of azole drug susceptibility by Candida albicans protein kinase CK2. *Molecular Microbiology*, **2005**, 56, 559-73	4.1	41
347	Population structure and properties of Candida albicans, as determined by multilocus sequence typing. **2005**, 43, 5601-13		152
346	Candida albicans zinc cluster protein Upc2p confers resistance to antifungal drugs and is an activator of ergosterol biosynthetic genes. *Antimicrobial Agents and Chemotherapy*, **2005**, 49, 1745-52	5.9	169
345	An update on antifungal targets and mechanisms of resistance in Candida albicans. **2005**, 43, 285-318		221
344	Expression of the CDR1 efflux pump in clinical Candida albicans isolates is controlled by a negative regulatory element. **2005**, 332, 206-14		19
343	cDNA microarray analysis of differential gene expression and regulation in clinically drug-resistant isolates of Candida albicans from bone marrow transplanted patients. **2006**, 296, 421-34		26
342	. **2006**,		1
341	[Antifungals cellular targets and mechanisms of resistance]. **2006**, 61, 195-9		3
340	Fungal ATP-binding cassette (ABC) transporters in drug resistance & detoxification. **2006**, 7, 471-81		75
339	Microarrays for Studying Pathogenicity in Candida Albicans. 181-209		16
338	Serum repressing efflux pump CDR1 in Candida albicans. **2006**, 7, 22		12
337	Key physiological differences in Candida albicans CDR1 induction by steroid hormones and antifungal drugs. **2006**, 23, 795-802		24
336	CRZ1, a target of the calcineurin pathway in Candida albicans. *Molecular Microbiology*, **2006**, 59, 1429-51	4.1	161
335	PDR16-mediated azole resistance in Candida albicans. *Molecular Microbiology*, **2006**, 60, 1546-62	4.1	57
334	Heterozygosity and functional allelic variation in the Candida albicans efflux pump genes CDR1 and CDR2. *Molecular Microbiology*, **2006**, 62, 170-86	4.1	58
333	Recent insights into the mechanisms of antifungal resistance. **2006**, 8, 449-56		41
332	Cap1p is involved in multiple pathways of oxidative stress response in Candida albicans. **2006**, 40, 1201-9		110

331	Efflux pumps in drug resistance of Candida. **2006**, 6, 69-83		50
330	The DNA-binding domain of CaNdt80p is required to activate CDR1 involved in drug resistance in Candida albicans. **2006**, 55, 1403-1411		20
329	A mutation in Tac1p, a transcription factor regulating CDR1 and CDR2, is coupled with loss of heterozygosity at chromosome 5 to mediate antifungal resistance in Candida albicans. **2006**, 172, 2139-56		279
328	Cellular and molecular biology of Candida albicans estrogen response. *Eukaryotic Cell*, **2006**, 5, 180-91		70
327	Transcriptional regulation of MDR1, encoding a drug efflux determinant, in fluconazole-resistant Candida albicans strains through an Mcm1p binding site. *Eukaryotic Cell*, **2006**, 5, 1957-68		50
326	Overexpression of Candida albicans CDR1, CDR2, or MDR1 does not produce significant changes in echinocandin susceptibility. *Antimicrobial Agents and Chemotherapy*, **2006**, 50, 1148-55	5.9	109
325	Aneuploidy and isochromosome formation in drug-resistant Candida albicans. **2006**, 313, 367-70		508
324	The CRH family coding for cell wall glycosylphosphatidylinositol proteins with a predicted transglycosidase domain affects cell wall organization and virulence of Candida albicans. **2006**, 281, 40399-411		90
323	A fungal family of transcriptional regulators: the zinc cluster proteins. **2006**, 70, 583-604		369
322	Multiple cis-acting sequences mediate upregulation of the MDR1 efflux pump in a fluconazole-resistant clinical Candida albicans isolate. *Antimicrobial Agents and Chemotherapy*, **2006**, 50, 2300-8	5.9	33
321	New Insights in Medical Mycology. **2007**,		4
320	The transcription factor Mrr1p controls expression of the MDR1 efflux pump and mediates multidrug resistance in Candida albicans. **2007**, 3, e164		235
319	Multidrug resistance in fungi. *Eukaryotic Cell*, **2007**, 6, 1933-42		112
318	Genome-wide expression and location analyses of the Candida albicans Tac1p regulon. *Eukaryotic Cell*, **2007**, 6, 2122-38		97
317	Genotypic evolution of azole resistance mechanisms in sequential Candida albicans isolates. *Eukaryotic Cell*, **2007**, 6, 1889-904		234
316	Proteomic analysis reveals a metabolism shift in a laboratory fluconazole-resistant Candida albicans strain. **2007**, 6, 2248-56		31
315	Chemosensitisation of drug-resistant and drug-sensitive yeast cells to antifungals. **2007**, 29, 170-8		19
314	The zinc cluster transcription factor Tac1p regulates PDR16 expression in Candida albicans. *Molecular Microbiology*, **2007**, 66, 440-52	4.1	73

313	A genome-wide steroid response study of the major human fungal pathogen Candida albicans. **2007**, 164, 1-17		27
312	Transcriptional regulators of seven yeast species: comparative genome analysis. Review. **2008**, 53, 275-87		7
311	Extensive Chemometric Investigations of the Multidrug Resistance in Strains of the Phytopathogenic Fungus Penicillium Digitatum. **2008**, 27, 289-301		1
310	Effect of commonly used herbicides on the virulence factor CDR1 in Candida albicans. **2008**, 27, 2346-51		4
309	The evolution of fungal drug resistance: modulating the trajectory from genotype to phenotype. **2008**, 6, 187-98		218
308	An isochromosome confers drug resistance in vivo by amplification of two genes, ERG11 and TAC1. *Molecular Microbiology*, **2008**, 68, 624-41	4.1	220
307	Mutations in the multi-drug resistance regulator MRR1, followed by loss of heterozygosity, are the main cause of MDR1 overexpression in fluconazole-resistant Candida albicans strains. *Molecular Microbiology*, **2008**, 69, 827-40	4.1	189
306	Transcriptomics of the Fungal Pathogens, Focusing on Candida albicans. **2008**, 187-222		3
305	Human and Animal Relationships. **2008**,		2
304	Outwitting multidrug resistance to antifungals. **2008**, 321, 367-9		109
303	A gain-of-function mutation in the transcription factor Upc2p causes upregulation of ergosterol biosynthesis genes and increased fluconazole resistance in a clinical Candida albicans isolate. *Eukaryotic Cell*, **2008**, 7, 1180-90		173
302	Evidence for the bifunctional nature of mitochondrial phosphatidylserine decarboxylase: role in Pdr3-dependent retrograde regulation of PDR5 expression. **2008**, 28, 5851-64		42
301	Transcriptional activation and increased mRNA stability contribute to overexpression of CDR1 in azole-resistant Candida albicans. *Antimicrobial Agents and Chemotherapy*, **2008**, 52, 1481-92	5.9	37
300	Responses of pathogenic and nonpathogenic yeast species to steroids reveal the functioning and evolution of multidrug resistance transcriptional networks. *Eukaryotic Cell*, **2008**, 7, 68-77		32
299	Divergent functions of three Candida albicans zinc-cluster transcription factors (CTA4, ASG1 and CTF1) complementing pleiotropic drug resistance in Saccharomyces cerevisiae. **2008**, 154, 1491-1501		32
298	ABC transporter Cdr1p contributes more than Cdr2p does to fluconazole efflux in fluconazole-resistant Candida albicans clinical isolates. *Antimicrobial Agents and Chemotherapy*, **2008**, 52, 3851-62	5.9	119
297	Stress, drugs, and evolution: the role of cellular signaling in fungal drug resistance. *Eukaryotic Cell*, **2008**, 7, 747-64		201
296	Role of Ndt80p in sterol metabolism regulation and azole resistance in Candida albicans. *Eukaryotic Cell*, **2009**, 8, 1174-83		66

295	Relative contributions of the Candida albicans ABC transporters Cdr1p and Cdr2p to clinical azole resistance. *Antimicrobial Agents and Chemotherapy*, **2009**, 53, 1344-52	5.9	95
294	Identification of the Candida albicans Cap1p regulon. *Eukaryotic Cell*, **2009**, 8, 806-20		79
293	Acquisition of aneuploidy provides increased fitness during the evolution of antifungal drug resistance. **2009**, 5, e1000705		214
292	A phenotypic profile of the Candida albicans regulatory network. **2009**, 5, e1000783		292
291	Efflux in fungi: la pi□e de r□istance. **2009**, 5, e1000486		146
290	Nuclear receptor-like transcription factors in fungi. **2009**, 23, 419-32		38
289	Aneuploid chromosomes are highly unstable during DNA transformation of Candida albicans. *Eukaryotic Cell*, **2009**, 8, 1554-66		64
288	Efflux-mediated antifungal drug resistance. **2009**, 22, 291-321, Table of Contents		400
287	Glucose promotes stress resistance in the fungal pathogen Candida albicans. **2009**, 20, 4845-55		119
286	Functional analysis of cis- and trans-acting elements of the Candida albicans CDR2 promoter with a novel promoter reporter system. *Eukaryotic Cell*, **2009**, 8, 1250-67		63
285	The alternative oxidase of Candida albicans causes reduced fluconazole susceptibility. **2009**, 64, 764-73		61
284	Hypersusceptibility to azole antifungals in a clinical isolate of Candida glabrata with reduced aerobic growth. *Antimicrobial Agents and Chemotherapy*, **2009**, 53, 3034-41	5.9	17
283	Genetic Basis of Antifungal Drug Resistance. **2009**, 3, 163-169		35
282	Proteomic analysis of Mrr1p- and Tac1p-associated differential protein expression in azole-resistant clinical isolates of Candida albicans. **2009**, 3, 968-78		4
281	Promoter regulation in Candida albicans and related species. *FEMS Yeast Research*, **2009**, 9, 2-15	3.1	10
280	Ibuprofen reverts antifungal resistance on Candida albicans showing overexpression of CDR genes. *FEMS Yeast Research*, **2009**, 9, 618-25	3.1	40
279	Efficient and rapid identification of Candida albicans allelic status using SNP-RFLP. *FEMS Yeast Research*, **2009**, 9, 1061-9	3.1	28
278	In Candida albicans, resistance to flucytosine and terbinafine is linked to MAT locus homozygosity and multilocus sequence typing clade 1. *FEMS Yeast Research*, **2009**, 9, 1091-101	3.1	16

277	Antifungal drug resistance mechanisms in fungal pathogens from the perspective of transcriptional gene regulation. *FEMS Yeast Research*, **2009**, 9, 1029-50	3.1	182
276	Coordinate control of lipid composition and drug transport activities is required for normal multidrug resistance in fungi. **2009**, 1794, 852-9		48
275	Rep1p negatively regulating MDR1 efflux pump involved in drug resistance in Candida albicans. **2009**, 46, 714-20		28
274	Antifungal Targets, Mechanisms of Action, and Resistance in Candida albicans. **2009**, 347-407		4
273	Antifungal drug resistance: do molecular methods provide a way forward?. **2009**, 22, 568-73		75
272	A novel polyamide SL-A92 as a potential fungal resistance blocker: synthesis and bioactivities in Candida albicans. **2010**, 31, 855-60		4
271	Genetic dissection of azole resistance mechanisms in Candida albicans and their validation in a mouse model of disseminated infection. *Antimicrobial Agents and Chemotherapy*, **2010**, 54, 1476-83	5.9	88
270	Persistent Candida albicans colonization and molecular mechanisms of azole resistance in autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED) patients. **2010**, 65, 2505-13		51
269	Fluconazole transport into Candida albicans secretory vesicles by the membrane proteins Cdr1p, Cdr2p, and Mdr1p. *Eukaryotic Cell*, **2010**, 9, 960-70		18
268	Mechanism of the synergistic effect of amiodarone and fluconazole in Candida albicans. *Antimicrobial Agents and Chemotherapy*, **2010**, 54, 1753-61	5.9	58
267	PAP1 [poly(A) polymerase 1] homozygosity and hyperadenylation are major determinants of increased mRNA stability of CDR1 in azole-resistant clinical isolates of Candida albicans. **2010**, 156, 313-326		18
266	An A643T mutation in the transcription factor Upc2p causes constitutive ERG11 upregulation and increased fluconazole resistance in Candida albicans. *Antimicrobial Agents and Chemotherapy*, **2010**, 54, 353-9	5.9	95
265	Antifungal curcumin induces reactive oxygen species and triggers an early apoptosis but prevents hyphae development by targeting the global repressor TUP1 in Candida albicans. **2010**, 30, 391-404		96
264	Comparative functional genomics of stress responses in yeasts. **2010**, 14, 501-15		9
263	Regulation of multidrug resistance in pathogenic fungi. **2010**, 47, 94-106		215
262	Antimicrobial Resistance in Developing Countries. **2010**,		48
261	Regulation of efflux pump expression and drug resistance by the transcription factors Mrr1, Upc2, and Cap1 in Candida albicans. *Antimicrobial Agents and Chemotherapy*, **2011**, 55, 2212-23	5.9	84
260	The transcription factor Ndt80 does not contribute to Mrr1-, Tac1-, and Upc2-mediated fluconazole resistance in Candida albicans. **2011**, 6, e25623		43

259	In vivo systematic analysis of Candida albicans Zn2-Cys6 transcription factors mutants for mice organ colonization. **2011**, 6, e26962		33
258	Candida albicans Colonization and Community Development. **2011**, 163		
257	Metallopeptidase inhibitors arrest vital biological processes in the fungal pathogen Scedosporium apiospermum. **2011**, 54, 105-12		11
256	Rad52 function prevents chromosome loss and truncation in Candida albicans. *Molecular Microbiology*, **2011**, 79, 1462-82	4.1	27
255	An MDR1 promoter allele with higher promoter activity is common in clinically isolated strains of Candida albicans. **2011**, 286, 347-57		6
254	Diagnosis of Antifungal Drug Resistance Mechanisms in Fungal Pathogens: Transcriptional Gene Regulation. **2011**, 5, 157-167		5
253	Development of a novel multiplex DNA microarray for Fusarium graminearum and analysis of azole fungicide responses. **2011**, 12, 52		68
252	Doxorubicin induces drug efflux pumps in Candida albicans. **2011**, 49, 132-42		16
251	Loss of heterozygosity of FCY2 leading to the development of flucytosine resistance in Candida tropicalis. *Antimicrobial Agents and Chemotherapy*, **2011**, 55, 2506-14	5.9	14
250	Voriconazole-induced inhibition of the fungicidal activity of amphotericin B in Candida strains with reduced susceptibility to voriconazole: an effect not predicted by the MIC value alone. *Antimicrobial Agents and Chemotherapy*, **2011**, 55, 1629-37	5.9	5
249	Ncb2 is involved in activated transcription of CDR1 in azole-resistant clinical isolates of Candida albicans. *Eukaryotic Cell*, **2011**, 10, 1357-66		15
248	Functional dissection of a Candida albicans zinc cluster transcription factor, the multidrug resistance regulator Mrr1. *Eukaryotic Cell*, **2011**, 10, 1110-21		29
247	Transcriptional profiling of azole-resistant Candida parapsilosis strains. *Antimicrobial Agents and Chemotherapy*, **2011**, 55, 3546-56	5.9	60
246	Regulatory circuitry governing fungal development, drug resistance, and disease. **2011**, 75, 213-67		365
245	Molecular determinants of transient and reversible induced up-regulation of CaCDR1 in azole susceptible clinical isolates of Candida albicans. **2011**, 31, 31-43		1
244	Identification and functional characterization of Rca1, a transcription factor involved in both antifungal susceptibility and host response in Candida albicans. *Eukaryotic Cell*, **2012**, 11, 916-31		38
243	Azole resistance by loss of function of the sterol □desaturase gene (ERG3) in Candida albicans does not necessarily decrease virulence. *Antimicrobial Agents and Chemotherapy*, **2012**, 56, 1960-8	5.9	68
242	Gain-of-function mutations in UPC2 are a frequent cause of ERG11 upregulation in azole-resistant clinical isolates of Candida albicans. *Eukaryotic Cell*, **2012**, 11, 1289-99		139

241	Antifungal resistance and new strategies to control fungal infections. **2012**, 2012, 713687		257
240	The stepwise acquisition of fluconazole resistance mutations causes a gradual loss of fitness in Candida albicans. *Molecular Microbiology*, **2012**, 86, 539-56	4.1	57
239	Analyzing fission yeast multidrug resistance mechanisms to develop a genetically tractable model system for chemical biology. **2012**, 19, 893-901		28
238	The fungicide fludioxonil antagonizes fluconazole activity in the human fungal pathogen Candida albicans. **2012**, 61, 1696-1703		6
237	Response of pathogenic and non-pathogenic yeasts to steroids. **2012**, 129, 61-9		11
236	Arv1 lipid transporter function is conserved between pathogenic and nonpathogenic fungi. **2012**, 49, 101-13		9
235	RNA sequencing revealed novel actors of the acquisition of drug resistance in Candida albicans. **2012**, 13, 396		29
234	The cellular and molecular defense mechanisms of the Candida yeasts against azole antifungal drugs. *Journal De Mycologie Medicale*, **2012**, 22, 173-8	3	27
233	Functional characterization of the small heat shock protein Hsp12p from Candida albicans. **2012**, 7, e42894		19
232	Chromosome 5 monosomy of Candida albicans controls susceptibility to various toxic agents, including major antifungals. *Antimicrobial Agents and Chemotherapy*, **2013**, 57, 5026-36	5.9	40
231	Molecular mechanisms of drug resistance in clinical Candida species isolated from Tunisian hospitals. *Antimicrobial Agents and Chemotherapy*, **2013**, 57, 3182-93	5.9	84
230	Gain-of-function mutation in the KlPDR1 gene encoding multidrug resistance regulator in Kluyveromyces lactis. **2013**, 30, 71-80		1
229	Deciphering azole resistance mechanisms with a focus on transcription factor-encoding genes TAC1, MRR1 and UPC2 in a set of fluconazole-resistant clinical isolates of Candida albicans. **2013**, 42, 410-5		25
228	Ploidy variation as an adaptive mechanism in human pathogenic fungi. **2013**, 24, 339-46		47
227	Molecular fingerprints to identify Candida species. **2013**, 2013, 923742		8
226	Candida infections, causes, targets, and resistance mechanisms: traditional and alternative antifungal agents. **2013**, 2013, 204237		179
225	Milbemycins: more than efflux inhibitors for fungal pathogens. *Antimicrobial Agents and Chemotherapy*, **2013**, 57, 873-86	5.9	34
224	Mitochondria influence CDR1 efflux pump activity, Hog1-mediated oxidative stress pathway, iron homeostasis, and ergosterol levels in Candida albicans. *Antimicrobial Agents and Chemotherapy*, **2013**, 57, 5580-99	5.9	63

223	Synergy of the antibiotic colistin with echinocandin antifungals in Candida species. **2013**, 68, 1285-96		37
222	Novel Regulatory Mechanisms of Pathogenicity and Virulence to Combat MDR in Candida albicans. **2013**, 2013, 240209		15
221	Azole susceptibility and transcriptome profiling in Candida albicans mitochondrial electron transport chain complex I mutants. *Antimicrobial Agents and Chemotherapy*, **2013**, 57, 532-42	5.9	66
220	Analysis of a fungus-specific transcription factor family, the Candida albicans zinc cluster proteins, by artificial activation. *Molecular Microbiology*, **2013**, 89, 1003-17	4.1	45
219	Contributions of Aspergillus fumigatus ATP-binding cassette transporter proteins to drug resistance and virulence. *Eukaryotic Cell*, **2013**, 12, 1619-28		56
218	Evolution of Drug Resistance in Fungi. **2013**, 143-167		
217	Molecular mechanisms of action of herbal antifungal alkaloid berberine, in Candida albicans. **2014**, 9, e104554		55
216	Transcriptomics in Health and Disease. **2014**,		0
215	CZT-1 is a novel transcription factor controlling cell death and natural drug resistance in Neurospora crassa. **2014**, 4, 1091-102		14
214	The Ins and Outs of Azole Antifungal Drug Resistance: Molecular Mechanisms of Transport. **2014**, 1-27		3
213	Mechanisms of Drug Resistance in Fungi and Their Significance in Biofilms. **2014**, 45-65		7
212	Microevolution of Antifungal Drug Resistance. **2014**, 1-21		
211	Multidrug resistance in fungi: regulation of transporter-encoding gene expression. **2014**, 5, 143		79
210	Distinct roles of Candida albicans drug resistance transcription factors TAC1, MRR1, and UPC2 in virulence. *Eukaryotic Cell*, **2014**, 13, 127-42		59
209	Novel antifungal drug discovery based on targeting pathways regulating the fungus-conserved Upc2 transcription factor. *Antimicrobial Agents and Chemotherapy*, **2014**, 58, 258-66	5.9	27
208	UPC2 is universally essential for azole antifungal resistance in Candida albicans. *Eukaryotic Cell*, **2014**, 13, 933-46		34
207	Disruption of the transcriptional regulator Cas5 results in enhanced killing of Candida albicans by Fluconazole. *Antimicrobial Agents and Chemotherapy*, **2014**, 58, 6807-18	5.9	26
206	Fine-Scale Chromosomal Changes in Fungal Fitness. **2014**, 8, 171-178		1

205	Novel role of a family of major facilitator transporters in biofilm development and virulence of Candida albicans. **2014**, 460, 223-35		44
204	Elucidating drug resistance in human fungal pathogens. **2014**, 9, 523-42		57
203	The Fungal Pathogen Candida albicans. **2014**, 751-768		
202	Berberine inhibits fluphenazine-induced up-regulation of CDR1 in Candida albicans. **2014**, 37, 268-73		8
201	Estimation of Candida albicans ABC Transporter Behavior in Real-Time via Fluorescence. **2015**, 6, 1382		13
200	Update on Antifungal Drug Resistance. **2015**, 2, 84-95		105
199	Stepwise emergence of azole, echinocandin and amphotericin B multidrug resistance in vivo in Candida albicans orchestrated by multiple genetic alterations. **2015**, 70, 2551-5		43
198	Cph1p negatively regulates MDR1 involved in drug resistance in Candida albicans. **2015**, 45, 617-21		11
197	Next-generation sequencing offers new insights into the resistance of Candida spp. to echinocandins and azoles. **2015**, 70, 2556-65		34
196	Induction of Candida albicans drug resistance genes by hybrid zinc cluster transcription factors. *Antimicrobial Agents and Chemotherapy*, **2015**, 59, 558-69	5.9	16
195	Fitness Trade-Offs Associated with the Evolution of Resistance to Antifungal Drug Combinations. **2015**, 10, 809-819		38
194	Multiple mechanisms contribute to the development of clinically significant azole resistance in Aspergillus fumigatus. **2015**, 6, 70		35
193	Candida albicans mutant construction and characterization of selected virulence determinants. **2015**, 115, 153-65		7
192	Detection of inhibitors of Candida albicans Cdr transporters using a diS-C3(3) fluorescence. **2015**, 6, 176		16
191	Mechanisms of azole resistance in Candida albicans clinical isolates from Shanghai, China. **2015**, 166, 153-61		34
190	Development of fluconazole resistance in a series of Candida parapsilosis isolates from a persistent candidemia patient with prolonged antifungal therapy. **2015**, 15, 340		40
189	Mutations in transcription factor Mrr2p contribute to fluconazole resistance in clinical isolates of Candida albicans. **2015**, 46, 552-9		11
188	Medically important fungi respond to azole drugs: an update. **2015**, 10, 1355-73		41

187	Pleiotropic drug-resistance attenuated genomic library improves elucidation of drug mechanisms. **2015**, 11, 3129-36		10
186	Mechanisms of Antifungal Drug Resistance. **2014**, 5, a019752		262
185	Genetic determinants of antifungal resistance in Candida species. **2016**, 15, 2259-2264		
184	Novel point mutations in the ERG11 gene in clinical isolates of azole resistant Candida species. **2016**, 111, 192-9		21
183	Transcriptional Control of Drug Resistance, Virulence and Immune System Evasion in Pathogenic Fungi: A Cross-Species Comparison. *Frontiers in Cellular and Infection Microbiology*, **2016**, 6, 131	5.9	14
182	Emerging Threats in Antifungal-Resistant Fungal Pathogens. **2016**, 3, 11		237
181	Multidrug efflux pumps as main players in intrinsic and acquired resistance to antimicrobials. **2016**, 28, 13-27		87
180	Vulvovaginal candidosis: contemporary challenges and the future of prophylactic and therapeutic approaches. **2016**, 59, 262-73		30
179	Biological Characterization and in Vivo Assessment of the Activity of a New Synthetic Macrocyclic Antifungal Compound. **2016**, 59, 3854-66		15
178	The RTA3 Gene, Encoding a Putative Lipid Translocase, Influences the Susceptibility of Candida albicans to Fluconazole. *Antimicrobial Agents and Chemotherapy*, **2016**, 60, 6060-6	5.9	17
177	Positive regulation of the Candida albicans multidrug efflux pump Cdr1p function by phosphorylation of its N-terminal extension. **2016**, 71, 3125-3134		13
176	Beauvericin Potentiates Azole Activity via Inhibition of Multidrug Efflux, Blocks Candida albicans Morphogenesis, and Is Effluxed via Yor1 and Circuitry Controlled by Zcf29. *Antimicrobial Agents and Chemotherapy*, **2016**, 60, 7468-7480	5.9	34
175	Yeast ABC transporters in lipid trafficking. **2016**, 93, 25-34		25
174	Different Facets of Copy Number Changes: Permanent, Transient, and Adaptive. **2016**, 36, 1050-63		31
173	Budding off: bringing functional genomics to Candida albicans. **2016**, 15, 85-94		7
172	The development of fluconazole resistance in Candida albicans - an example of microevolution of a fungal pathogen. **2016**, 54, 192-201		65
171	Mycologic Endocrinology. **2016**, 874, 337-63		5
170	Activity of Isavuconazole and Other Azoles against Candida Clinical Isolates and Yeast Model Systems with Known Azole Resistance Mechanisms. *Antimicrobial Agents and Chemotherapy*, **2016**, 60, 229-38	5.9	45

169	Contributions of both ATP-Binding Cassette Transporter and Cyp51A Proteins Are Essential for Azole Resistance in Aspergillus fumigatus. *Antimicrobial Agents and Chemotherapy*, **2017**, 61,	5.9	24
168	Triazole Resistance in Aspergillus Species: An Emerging Problem. **2017**, 77, 599-613		76
167	Mechanisms of Drug Resistance in Candida albicans. **2017**, 287-311		5
166	Using Yeast to Discover Inhibitors of Multidrug Efflux in Candida albicans. **2017**, 491-543		1
165	Microevolution of Antifungal Drug Resistance. **2017**, 345-368		
164	Competitive Fitness of Fluconazole-Resistant Clinical Candida albicans Strains. *Antimicrobial Agents and Chemotherapy*, **2017**, 61,	5.9	20
163	The global regulator Ncb2 escapes from the core promoter and impacts transcription in response to drug stress in Candida albicans. **2017**, 7, 46084		7
162	The Ins and Outs of Azole Antifungal Drug Resistance: Molecular Mechanisms of Transport. **2017**, 423-452		5
161	Azole resistance in Candida albicans from animals: Highlights on efflux pump activity and gene overexpression. **2017**, 60, 462-468		23
160	Multidrug-Resistant Candida: Epidemiology, Molecular Mechanisms, and Treatment. **2017**, 216, S445-S451		258
159	Mediator Tail Module Is Required for Tac1-Activated Expression and Azole Resistance in Candida albicans. *Antimicrobial Agents and Chemotherapy*, **2017**, 61,	5.9	24
158	Adaptive Mistranslation Accelerates the Evolution of Fluconazole Resistance and Induces Major Genomic and Gene Expression Alterations in. **2017**, 2,		15
157	Candidiasis and the impact of flow cytometry on antifungal drug discovery. **2017**, 12, 1127-1137		
156	Distinct roles of the 7-transmembrane receptor protein Rta3 in regulating the asymmetric distribution of phosphatidylcholine across the plasma membrane and biofilm formation in Candida albicans. **2017**, 19, e12767		9
155	Candida albicans Swi/Snf and Mediator Complexes Differentially Regulate Mrr1-Induced Expression and Fluconazole Resistance. *Antimicrobial Agents and Chemotherapy*, **2017**, 61,	5.9	19
154	Azole Antifungal Resistance in and Emerging Non- Species. **2016**, 7, 2173		329
153	A CTG Clade Candida Yeast Genetically Engineered for the Genotype-Phenotype Characterization of Azole Antifungal Resistance in Human-Pathogenic Yeasts. *Antimicrobial Agents and Chemotherapy*, **2018**, 62,	5.9	4
152	A Hyperactive Form of the Zinc Cluster Transcription Factor Stb5 Causes Overexpression and Beauvericin Resistance in Candida albicans. *Antimicrobial Agents and Chemotherapy*, **2018**, 62,	5.9	6

151	Efflux pump-mediated resistance to antifungal compounds can be prevented by conjugation with triphenylphosphonium cation. **2018**, 9, 5102		25
150	Evolutionary Emergence of Drug Resistance in Candida Opportunistic Pathogens. **2018**, 9,		81
149	Evolution of drug resistance in an antifungal-naive chronic infection. **2018**, 115, 12040-12045		28
148	Implications of the EUCAST Trailing Phenomenon in Candida tropicalis for the Susceptibility in Invertebrate and Murine Models. *Antimicrobial Agents and Chemotherapy*, **2018**, 62,	5.9	17
147	Candida albicans Zn Cluster Transcription Factors Tac1 and Znc1 Are Activated by Farnesol To Upregulate a Transcriptional Program Including the Multidrug Efflux Pump. *Antimicrobial Agents and Chemotherapy*, **2018**, 62,	5.9	9
146	Abnormal Ergosterol Biosynthesis Activates Transcriptional Responses to Antifungal Azoles. **2018**, 9, 9		46
145	Infections and Therapeutic Strategies: Mechanisms of Action for Traditional and Alternative Agents. **2018**, 9, 1351		85
144	Candidacidal Activity of a Novel Killer Toxin from Wickerhamomyces anomalus against Fluconazole-Susceptible and -Resistant Strains. **2018**, 10,		4
143	Host-Pathogen Interactions Mediated by MDR Transporters in Fungi: As Pleiotropic as it Gets!. **2018** , 9,		15
142	Global analysis of genetic circuitry and adaptive mechanisms enabling resistance to the azole antifungal drugs. **2018**, 14, e1007319		15
141	Frontier in Antifungal Treatments Against Major Human Fungal Opportunistic Pathogen Candida Species and Medically Important Fungi. **2019**, 453-476		1
140	: The Canary in the Mine of Antifungal Drug Resistance. **2019**, 5, 1487-1492		10
139	Multidrug transporters of Candida species in clinical azole resistance. **2019**, 132, 103252		16
138	Facilitators of adaptation and antifungal resistance mechanisms in clinically relevant fungi. **2019**, 132, 103254		26
137	Establishment, Hybridization, Dispersal, Impact, and Decline of Diorhabda spp. (Coleoptera: Chrysomelidae) Released for Biological Control of Tamarisk in Texas and New Mexico. **2019**, 48, 1297-1316		3
136	Molecular and genetic basis of azole antifungal resistance in the opportunistic pathogenic fungus Candida albicans. **2020**, 75, 257-270		29
135	FLO8 deletion leads to azole resistance by upregulating CDR1 and CDR2 in Candida albicans. **2019**, 170, 272-279		6
134	Evidence that Ergosterol Biosynthesis Modulates Activity of the Pdr1 Transcription Factor in Candida glabrata. **2019**, 10,		26

133	Detection of ERG11 point mutations in Iranian fluconazole-resistant isolates. **2019**, 5, 7-14		7
132	Missense mutation in CgPDR1 regulator associated with azole-resistant Candida glabrata recovered from Thai oral candidiasis patients. **2019**, 17, 221-226		2
131	Contribution of Clinically Derived Mutations in the Gene Encoding the Zinc Cluster Transcription Factor Mrr2 to Fluconazole Antifungal Resistance and Expression in. *Antimicrobial Agents and Chemotherapy*, **2019**, 63,	5.9	6
130	Physiological Genomics of Multistress Resistance in the Yeast Cell Model and Factory: Focus on MDR/MXR Transporters. **2019**, 58, 1-35		2
129	A Systematic Screen Reveals a Diverse Collection of Medications That Induce Antifungal Resistance in Species. *Antimicrobial Agents and Chemotherapy*, **2019**, 63,	5.9	6
128	Expression of fluconazole resistance-associated genes in biofilm from 23 clinical isolates of Candida albicans. **2019**, 50, 157-163		12
127	Evolution of Fluconazole-Resistant Candida albicans Strains by Drug-Induced Mating Competence and Parasexual Recombination. **2019**, 10,		19
126	Candida parapsilosis: from Genes to the Bedside. **2019**, 32,		93
125	Comparative Genomics for the Elucidation of Multidrug Resistance in Candida lusitaniae. **2019**, 10,		15
124	Anticandidal agent for multiple targets: the next paradigm in the discovery of proficient therapeutics/overcoming drug resistance. **2019**, 11, 2955-2974		4
123	Unveiling the transcriptional control of pleiotropic drug resistance in Saccharomyces cerevisiae: Contributions of Andr Goffeau and his group. **2019**, 36, 195-200		5
122	Analysis of antifungal resistance genes in Candida albicans and Candida glabrata using next generation sequencing. **2019**, 14, e0210397		30
121	Fungal Lanosterol 14 demethylase: A target for next-generation antifungal design. **2020**, 1868, 140206		27
120	On the standard Galerkin method with explicit RK4 time stepping for the shallow water equations. **2020**, 40, 2415-2449		2
119	The Impact of Gene Dosage and Heterozygosity on The Diploid Pathobiont. *Journal of Fungi (Basel, Switzerland)*, **2019**, 6,	5.6	10
118	Ifu5, a WW domain-containing protein interacts with Efg1 to achieve coordination of normoxic and hypoxic functions to influence pathogenicity traits in Candida albicans. **2020**, 22, e13140		2
117	Vanillin confers antifungal drug synergism in Candida albicans by impeding CaCdr2p driven efflux. *Journal De Mycologie Medicale*, **2020**, 30, 100921	3	4
116	Experimental Evolution Identifies Adaptive Aneuploidy as a Mechanism of Fluconazole Resistance in Candida auris. *Antimicrobial Agents and Chemotherapy*, **2020**, 65,	5.9	16

115	Transcription factors and ABC transporters: from pleiotropic drug resistance to cellular signaling in yeast. **2020**, 594, 3943-3964		8
114	Genomic Multiplication and Drug Efflux Influence Ketoconazole Resistance in. *Frontiers in Cellular and Infection Microbiology*, **2020**, 10, 191	5.9	5
113	Mutations in : a Novel Genetic Determinant of Clinical Fluconazole Resistance in Candida auris. **2020**, 11,		52
112	Repurposing approach identifies pitavastatin as a potent azole chemosensitizing agent effective against azole-resistant Candida species. **2020**, 10, 7525		12
111	Synthesis, crystal structure and in´vitro antifungal activity of two-dimensional silver(I)-voriconazole coordination complexes. **2020**, 1215, 128229		7
110	Single yeast cell nanomotions correlate with cellular activity. **2020**, 6, eaba3139		6
109	The H741D mutation in Tac1p contributes to the upregulation of CDR1 and CDR2 expression in Candida albicans. **2020**, 51, 1553-1561		0
108	Candida glabrata Transcription Factor Rpn4 Mediates Fluconazole Resistance through Regulation of Ergosterol Biosynthesis and Plasma Membrane Permeability. *Antimicrobial Agents and Chemotherapy*, **2020**, 64,	5.9	9
107	An Overview on Conventional and Non-Conventional Therapeutic Approaches for the Treatment of Candidiasis and Underlying Resistance Mechanisms in Clinical Strains. *Journal of Fungi (Basel, Switzerland)*, **2020**, 6,	5.6	13
106	Transcriptional control of hyphal morphogenesis in Candida albicans. *FEMS Yeast Research*, **2020**, 20,	3.1	17
105	Antifungal Resistance and Tolerance in Bloodstream Infections: The Triad Yeast-Host-Antifungal. **2020**, 8,		39
104	Machine Learning Approach for Fluconazole Resistance Detection Using Matrix-Assisted Laser Desorption/Ionization Time-of-Flight Mass Spectrometry. **2019**, 10, 3000		17
103	Large-scale genome mining allows identification of neutral polymorphisms and novel resistance mutations in genes involved in Candida albicans resistance to azoles and echinocandins. **2020**, 75, 835-848		6
102	Ospemifene displays broad-spectrum synergistic interactions with itraconazole through potent interference with fungal efflux activities. **2020**, 10, 6089		9
101	A Zinc Cluster Transcription Factor Contributes to the Intrinsic Fluconazole Resistance of Candida auris. **2020**, 5,		18
100	Azole Antifungal Drugs: Mode of Action and Resistance. **2021**, 427-437		4
99	What do we know about the biology of the emerging fungal pathogen of humans Candida auris?. **2021**, 242, 126621		11
98	A biological and genomic comparison of a drug-resistant and a drug-susceptible strain of isolated from Beijing, China. **2021**, 12, 1388-1399		2

97	targets that potentially synergize with fluconazole. **2021**, 47, 323-337		4
96	Function Analysis of MBF1, a Factor Involved in the Response to Amino Acid Starvation and Virulence in Candida albicans. **2021**, 2,		0
95	Mechanisms of Candida´Resistance to Antimycotics and Promising Ways to Overcome It: The Role of Probiotics. **2021**, 13, 926-948		4
94	Aequorin as a Useful Calcium-Sensing Reporter in. *Journal of Fungi (Basel, Switzerland)*, **2021**, 7,	5.6	
93	Novel and mutations associated with azole resistance in. *Antimicrobial Agents and Chemotherapy*, **2021**,	5.9	9
92	Genome-Wide Analysis of Experimentally Evolved Candida auris Reveals Multiple Novel Mechanisms of Multidrug Resistance. **2021**, 12,		19
91	Azole resistance is mediated by integration of sterol gene regulation and membrane transporter production by the zinc cluster-containing transcription factor Upc2A in Candida glabrata.		1
90	Cell Wall Proteome Profiling of a Fluconazole-Resistant Strain from a Lebanese Hospital Patient Using Tandem Mass Spectrometry-A Pilot Study. **2021**, 9,		0
89	Multiple roles of ABC transporters in yeast. **2021**, 150, 103550		6
88	Germination of a Field: Women in Candida albicans Research. **2021**, 8, 139-151		
87	PDR Transporter Is Involved in the Innate Azole Resistance of the Human Fungal Pathogen. **2021**, 12, 673206		1
86	Mitochondrial perturbation reduces susceptibility to xenobiotics through altered efflux in Candida albicans. **2021**, 219,		0
85	Development and Optimization of Luliconazole Spanlastics to Augment the Antifungal Activity against. **2021**, 13,		1
84	Resistance to Antifungal Drugs. **2021**, 35, 279-311		8
83	Transcriptome Variations in in Response to Two Different Inorganic Nitrogen Sources. **2021**, 12, 712701		1
82	Antimycotic Drugs and their Mechanisms of Resistance to Candida Species. **2021**,		0
81	The Candida glabrata Upc2A transcription factor is a global regulator of antifungal drug resistance pathways. **2021**, 17, e1009582		3
80	Participation of the ABC Transporter in Azole Resistance of. *Journal of Fungi (Basel, Switzerland)*, **2021**, 7,	5.6	1

79	Epidemiological Characterization of Clinical Fungal Isolates from Pauls Stradin Clinical University Hospital, Latvia: A 4-Year Surveillance Report. **2021**, 11,		0
78	Overexpression approaches to advance understanding of Candida albicans. *Molecular Microbiology*, **2021**,	4.1	1
77	Camphor and Eucalyptol-Anticandidal Spectrum, Antivirulence Effect, Efflux Pumps Interference and Cytotoxicity. **2021**, 22,		11
76	Mycologic Endocrinology. **2010**, 269-290		7
75	Resistance to Antifungal Drugs. **2011**, 135-151		1
74	Antifungal Targets, Mechanisms of Action, and Resistance in Candida albicans. **2017**, 429-475		1
73	Structure Function Analyses of Multidrug Transporters. **2017**, 379-406		2
72	Chain-length-specific anti-Candida activity of cationic lipo-oxazoles: a new class of quaternary ammonium compounds. **2017**, 66, 1706-1714		4
71	A chromosome 4 trisomy contributes to increased fluconazole resistance in a clinical isolate of Candida albicans. **2017**, 163, 856-865		21
70	Genome-wide analysis of experimentally evolved*Candida auris*reveals multiple novel mechanisms of multidrug-resistance.		3
69	Clearing the FoG: Antifungal tolerance is a subpopulation effect that is distinct from resistance and is associated with persistent candidemia.		2
68	Molecular Principles of Antifungal Drug Resistance. 197-212		5
67	Mechanisms of Resistance to Antifungal Agents. **2011**, 2008-2019		1
66	Contribution of CgPDR1-regulated genes in enhanced virulence of azole-resistant Candida glabrata. **2011**, 6, e17589		85
65	Clonal Strain Persistence of Candida albicans Isolates from Chronic Mucocutaneous Candidiasis Patients. **2016**, 11, e0145888		14
64	Candida glabrata Binding to Candida albicans Hyphae Enables Its Development in Oropharyngeal Candidiasis. **2016**, 12, e1005522		88
63	An acquired mechanism of antifungal drug resistance simultaneously enables Candida albicans to escape from intrinsic host defenses. **2017**, 13, e1006655		24
62	Proteomic analysis of cytosolic proteins associated with petite mutations in Candida glabrata. **2010** , 43, 1203-14		6

61	[Pleiotropic drug resistance ABC transporters in fungi]. **2011**, 33, 1048-56		2
60	Expandable and reversible copy number amplification drives rapid adaptation to antifungal drugs. **2020**, 9,		24
59	The Antifungal Pipeline: Fosmanogepix, Ibrexafungerp, Olorofim, Opelconazole, and Rezafungin. **2021**, 81, 1703-1729		25
58	Effects of oestrogen on vulvovaginal candidosis. **2021**,		1
57	Application of Machine Learning Classifier to Drug Resistance Analysis. *Frontiers in Cellular and Infection Microbiology*, **2021**, 11, 742062	5.9	4
56	Candida Albicans: New Insights in Infection, Disease, and Treatment. **2007**, 99-129		
55	Fungal Drug Resistance: Azoles. **2009**, 307-312		
54	Antifungal Drug Resistance in Developing Countries. **2010**, 137-156		
53	Mechanisms of Multidrug Resistance in Fungal Pathogens. **2010**, 327-358		
52	Membrane Transporters in Pleiotropic Drug Resistance and Stress Response in Yeast and Fungal Pathogens. **2009**, 159-193		
51	Molecular Detection of Antifungal Resistance. **2011**, 677-684		
50	Transcriptome in Human Mycoses. **2014**, 227-263		
49	Genome Plasticity in Candida albicans. 303-325		
48	Evolution of Pathogenic Candida Species. 565-580		
47	Emergence and Evolution of Antifungal Resistance. 297-306		0
46	Specific Chromosome Alterations of Candida albicans: Mechanisms for Adaptation to Pathogenicity. 197-212		1
45	Multidrug Resistance Transcriptional Regulatory Networks in Candida. 403-416		
44	Mechanisms of Resistance to Antifungal Agents. 2236-2254		0

43	Fungal Drug Resistance: Azoles. **2017**, 397-405		1
42	C. albicans Zn Cluster Transcription Factors Tac1 and Znc1 are Activated by Farnesol to Up Regulate a Transcriptional Program Including the Multi-Drug Efflux Pump CDR1.		
41	Comparative genomics for the elucidation of multidrug resistance (MDR) inCandida lusitaniae.		
40	G-protein-coupled Receptors in Fungi. *Fungal Biology*, **2020**, 37-126	2.3	0
39	Fungal Zn(II)Cys Transcription Factor ADS-1 Regulates Drug Efflux and Ergosterol Metabolism under Antifungal Azole Stress. *Antimicrobial Agents and Chemotherapy*, **2021**, 65,	5.9	0
38	Crosstalk between calcineurin and the cell wall integrity pathways prevents chitin overexpression in Candida albicans. *Journal of Cell Science*, **2021**,	5.3	1
37	Acquisition of cross-azole tolerance and aneuploidy in Candida albicans strains evolved to posaconazole.		0
36	Characterization of the Transcription Factor CgMar1: Role in Azole Susceptibility.. *Journal of Fungi (Basel, Switzerland)*, **2022**, 8,	5.6	
35	Overview about Candida auris: What's up 12 years after its first description?. *Journal De Mycologie Medicale*, **2022**, 32, 101248	3	1
34	Quorum Sensing Molecules in Yeast Wastewater Treatment and Their Regulation of Yeast Cell Morphology. *SSRN Electronic Journal*,	1	
33	Evolution of antimicrobial drug resistance in human pathogenic fungi. **2022**, 53-70		0
32	Transcriptome in Human Mycoses. **2022**, 395-435		
31	Coordinated Regulation of Membrane Homeostasis and Drug Accumulation by Novel Kinase STK-17 in Response to Antifungal Azole Treatment.. *Microbiology Spectrum*, **2022**, 10, e0012722	8.9	0
30	The Application of Small Molecules to the Control of Typical Species Associated With Oral Infectious Diseases.. *Frontiers in Cellular and Infection Microbiology*, **2022**, 12, 816386	5.9	0
29	The Transcription Factor FgAtrR Regulates Asexual and Sexual Development, Virulence, and DON Production and Contributes to Intrinsic Resistance to Azole Fungicides in .. *Biology*, **2022**, 11,	4.9	0
28	Deciphering the Mrr1/Mdr1 Pathway in Azole Resistance of Candida auris.. *Antimicrobial Agents and Chemotherapy*, **2022**, e0006722	5.9	1
27	Genomic landscape of the DHA1 family in the newly emerged pathogen Candida auris and mapping substrate repertoire of the prominent member CauMdr1.		
26	What 'Omics Can Tell Us About Antifungal Adaptation.. *FEMS Yeast Research*, **2021**,	3.1	0

25	Resistance to miltefosine results from amplification of the RTA3 floppase or inactivation of flippases in Candida parapsilosis.		0
24	Hsa-miR-422a Originated from Short Interspersed Nuclear Element Increases Expression by Collaborating with NF-E2.. *Molecules and Cells*, **2022**,	3.5	
23	Data_Sheet_1.docx. **2020**,		
22	Data_Sheet_1.docx. **2020**,		
21	Image_1.pdf. **2020**,		
20	Image_2.pdf. **2020**,		
19	Table_1.pdf. **2020**,		
18	Image_1.PDF. **2018**,		
17	Table_1.XLSX. **2018**,		
16	Table_2.DOCX. **2018**,		
15	Table_3.DOCX. **2018**,		
14	Table_4.DOCX. **2018**,		
13	How Fungal Multidrug Transporters Mediate Hyperresistance Through DNA Amplification and Mutation. *Molecular Microbiology*,	4.1	1
12	Candida parapsilosis Mdr1B and Cdr1B Are Drivers of Mrr1-Mediated Clinical Fluconazole Resistance. *Antimicrobial Agents and Chemotherapy*,	5.9	0
11	Changes of Gene Expression in Candida albicans Isolates from Vaginal Infections by Effects of Zinc Oxide Nanoparticles and Fluconazole. *Jundishapur Journal of Microbiology*, **2022**, 15,	1.2	
10	Development and applications of a CRISPR activation system for facile genetic overexpression in Candida albicans.		0
9	Single nucleotide polymorphisms and chromosomal copy number variation may impact the Sporothrix brasiliensis antifungal susceptibility and sporotrichosis clinical outcomes. **2022**, 103743		0
8	Genomic landscape of the DHA1 family in Candida auris and mapping substrate repertoire of CauMdr1.		0

7	Development and applications of a CRISPR activation system for facile genetic overexpression in Candida albicans.	0
6	Fingerprint SRS Imaging Unveils Ergosteryl Ester as a Metabolic Signature of Azole-ResistantCandida albicans.	0
5	Candida parapsilosis Virulence and Antifungal Resistance Mechanisms: A Comprehensive Review of Key Determinants. **2023**, 9, 80	1
4	Interplay between acetylation and ubiquitination of imitation switch chromatin remodeler Isw1 confers multidrug resistance inCryptococcus neoformans.	0
3	Fungal diseases and antifungal drugs. **2023**, 33-64	0
2	Drug resistance in pathogenic species of Candida. **2023**, 293-303	0
1	Emergence of Multidrug Resistance Microbes: Bacteria, Fungi, and Viruses. **2023**, 28-67	0